Drug
SPG302
SPG302 is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 33.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_2
4
67%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Completed(1)
Terminated(2)
Other(1)
Detailed Status
Active, not recruiting2
Terminated2
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
unknown117%
active_not_recruiting233%
completed117%
terminated233%
Recent Activity
2 active trials
Showing 5 of 6
unknown
Intermediate-size Patient Population Expanded Access Protocol
NCT07088159
active_not_recruitingphase_2
Study of SPG302 in Adults With Schizophrenia
NCT06442462
terminatedphase_2
Extension Study of Participants From SPG302-ALZ-101
NCT06833281
terminatedphase_2
Extension Study of Participants From SPG302-ALS-001
NCT06903286
active_not_recruitingphase_2
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
NCT06427668
Clinical Trials (6)
Showing 6 of 6 trials
NCT07088159
Intermediate-size Patient Population Expanded Access Protocol
NCT06442462Phase 2
Study of SPG302 in Adults With Schizophrenia
NCT06833281Phase 2
Extension Study of Participants From SPG302-ALZ-101
NCT06903286Phase 2
Extension Study of Participants From SPG302-ALS-001
NCT06427668Phase 2
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
NCT05882695Phase 1
Study of SPG302 in Healthy Volunteers and ALS Participants
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6